histone deacetylase

Type: Keyphrase
Name: histone deacetylase
First reported Apr 21 2014 - Updated Apr 21 2014 - 1 reports

Histone Deacetylase Inhibitors: Emerging Markets

WEST HARTFORD, Conn., April 21, 2014 /PRNewswire-iReach/ -- Global Information Inc. announces the addition of a new market research report "Histone Deacetylase Inhibitors: Emerging Markets" at GIIResearch.comThe global histone deacetylase inhibitor (HDI) ... [Published PR Newswire: Health - Apr 21 2014]
First reported Apr 16 2014 - Updated Apr 16 2014 - 1 reports

New Findings from Baylor University College of Medicine in the Area of Genetics Reported

By a News Reporter-Staff News Editor at Genomics & Genetics Weekly -- Investigators discuss new findings in Genetics. According to news reporting originating in Houston, Texas , by NewsRx journalists, research stated, "The silencing mediator of retinoic ... [Published 4 Traders - Apr 16 2014]
First reported Apr 15 2014 - Updated Apr 15 2014 - 1 reports

Discovery of the First N-Hydroxycinnamamide-Based Histone Deacetylase 1/3 Dual Inhibitors with Potent Oral Antitumor Activity

† Department of Medicinal Chemistry, School of Pharmacy, Shandong University, Ji’nan, Shandong 250012, P. R. China‡ Department of Drug Discovery and Biomedical Sciences, South Carolina College of Pharmacy, Medical University of South Carolina, Charleston, ... [Published Journal of Medicinal Chemistry - Apr 15 2014]
First reported Apr 15 2014 - Updated Apr 15 2014 - 1 reports

Inhibitors of histone deacetylase

This invention comprises the novel compounds of formula (I) wherein n, R1, R2, R3, R4, Q, X, Y, Z and have defined meanings, having histone deacetylase inhibiting enzymatic activity; their preparation, compositions containing them and their use as a ... [Published Free Patents Online - Apr 15 2014]
First reported Apr 15 2014 - Updated Apr 15 2014 - 1 reports

The histone deacetylase inhibitor, LBH589, promotes the systemic cytokine and effector responses of ...

Histone deacetylase (HDAC) inhibitors are a class of agents that have potent antitumor activity with a reported ability to upregulate MHC and costimulatory molecule expression. We hypothesized that epigenetic pharmacological immunomodulation could sensitize ... [Published 7thSpace - Apr 15 2014]
First reported Apr 08 2014 - Updated Apr 08 2014 - 1 reports

Cdc4 turns over Hst3 [Genetics]

Ellen R. Edenberg a , Ajay A. Vashisht b , Benjamin R. Topacio a , James A. Wohlschlegel b , and David P. Toczyski a , 1 a Department of Biochemistry and Biophysics, University of California, San Francisco, CA 94158; and b Department of Biological ... [Published PNAS - Apr 08 2014]
First reported Apr 04 2014 - Updated Apr 04 2014 - 1 reports

Epigenetic inheritance

in DNA, RNA, Epigenetics Research , North AmericaEpigenetics has become an area of growing interest as research uncovers the extent to which it plays a role in health and diseases. It’s of particular interest for many as diseases such as cancer have been ... [Published BioScreening - Apr 04 2014]
First reported Apr 01 2014 - Updated Apr 01 2014 - 1 reports

Histone deacetylase inhibitors based simultaneously on trisubstituted 1H-pyrroles and aromatic and heteroaromatic spacers

The present invention refers to compounds derived from trisubstituted 1H-pyrrole rings and aromatic rings, which have the following formula (I): wherein: R1 and R2 represent, independently, an optionally substituted C6-C10 aryl radical or an optionally ... [Published Free Patents Online - Apr 01 2014]
First reported Apr 01 2014 - Updated Apr 01 2014 - 1 reports

Enzyme inhibitors

Compounds of formula (I) are inhibitors of histone deacetylase activity, and are useful in the treatment of, for example, cancers ... [Published Free Patents Online - Apr 01 2014]
First reported Apr 01 2014 - Updated Apr 01 2014 - 1 reports

Spirocyclic compounds

The present invention relates to a novel class of substituted spirocyclic compounds. These compounds can inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis ... [Published Free Patents Online - Apr 01 2014]
First reported Mar 29 2014 - Updated Mar 29 2014 - 1 reports

3/28/14 - Taiwan Province of China,United States : TAIWAN cancer drug gets approval from FDA for clinical trials [TendersInfo (India)]

A Taiwan-developed anti-cancer drug was greenlighted by the US Food and Drug Administration (FDA) for phase 1 of human clinical trials.MPT0E028, a potent histone deacetylase inhibitor, is showing promising results in the treatment of cancer with test ... [Published Pharmacy Choice - Mar 29 2014]
First reported Mar 28 2014 - Updated Mar 28 2014 - 1 reports

Acetylon Pharmaceuticals Celebrates Headquarters Expansion in Boston's Innovation District

(NewsRx) -- By a News Reporter-Staff News Editor at Biotech Business Week -- Acetylon Pharmaceuticals, Inc., the leader in the development of selective histone deacetylase (HDAC) inhibitors for enhanced therapeutic outcomes, announced the expansion of ... [Published NewsRX - Mar 28 2014]

Quotes

...According to news reporting originating from Research Triangle Park, North Carolina , by NewsRx correspondents, research stated, "The regulatory networks of differentiation programs and the molecular mechanisms of lineage-specific gene regulation in mammalian embryos remain only partially defined. We document differential expression and temporal switching of BRG1-associated factor (BAF) subunits, core pluripotency factors and cardiac-specific genes during post-implantation development and subsequent early organogenesis."
Patrick Langlois, Chairman of the Board of Directors of BioAlliance Pharma, said: "Merging with Topotarget is a major milestone for BioAlliance Pharma. This transaction will result in a new and true leader in orphan oncology. I am confident that, under the leadership of Judith Greciet, the new entity will unleash its full potential and create value for our shareholders."
...According to news reporting out of Seoul, South Korea, by NewsRx editors, research stated, "Metastasis-associated protein 1 (MTA1) is a component of the nucleosome remodeling and histone deacetylase (HDAC) complex, which plays an important role in progression of breast cancer. Although MTA1 is known as a repressor of the transactivation function of estrogen receptor alpha (ER alpha), its involvement in the epigenetic control of transcription of the ER alpha gene ESR1 has not been studied."
"In one aspect, the invention provides a process for preparing romidepsin from a culture of Chromobacterium violaceum. The fermentation broth is acidified in order to inactivate or kill the microorganisms in the culture. The acidified fermentation broth is preliminarily purified by batch or column chromatography. Subsequently, multiple column chromatography steps may be used to achieve the desired level of purity. In certain embodiments, the first chromatography utilizes SEPABEADS SP850, a non-ionic adsorption resin. The romidepsin may be further purified by additional column chromatography steps. In certain embodiments, the romidepsin is subsequently purified by column chromatography using DIAION HP20SS resin, followed by column chromatography using DIAION HP20 resin, and finally by column chromatography on alumina. In certain embodiments, the column chromatography is performed at an apparent pH ranging from approximately 4 to approximately 6. In certain particular embodiments, the second column chromatography step is performed at a reduced apparent pH (e g., apparent pH of approximately 4 to 6). The romidepsin is optionally further purified by crystallization. One or more crystallization steps may be performed. In certain embodiments, the romidepsin is first crystallized using methanol and then crystallized using 85% aqueous acetone. The resulting romidepsin is then optionally filtered, washed, and dried. In certain embodiments, the crystallization steps or any subsequent steps are performed at a reduced apparent pH ranging from approximately 4.0 to approximately 6.0. It is particularly important that the final steps be performed at a reduced apparent pH since no subsequent purification steps are available for removing undesired contaminants. Any equipment (e g., tubing, pumps, filters, dryers, etc.) used in the fermentation and/or purification processes is washed with water or an acidic solution (e g., acetic acid) to remove or neutralize any alkaline residue on the equipment."

More Content

All (86) | News (81) | Reports (0) | Blogs (2) | Audio/Video (0) | Fact Sheets (0) | Press Releases (3)
sort by: Date | Relevance
Study Data from National Institute of Environme... [Published HispanicBusiness.com - 47 mins ago]
A high-content imaging assay for the quantifica... [Published 7thSpace - Apr 22 2014]
BioAlliance Pharma Acquires Biopharmaceutical F... [Published Bioresearch Online - Apr 21 2014]
Histone Deacetylase Inhibitors: Emerging Markets [Published PR Newswire: Health - Apr 21 2014]
BioAlliance Pharma, Topotarget to merge to crea... [Published PharmaBiz - Apr 18 2014]
BioAlliance Pharma and Topotarget to Merge [Published Individual.com - Apr 18 2014]
New Findings from Seoul National University in ... [Published NewsRX - Apr 18 2014]
Celgene : Patent Issued for Preparation of Romi... [Published 4 Traders - Apr 17 2014]
BioAlliance Pharma, Topotarget to merge [Published Center Watch - Apr 17 2014]
New Findings from Baylor University College of ... [Published 4 Traders - Apr 16 2014]
Quantitative Trait Loci (QTL) Study Identifies ... [Published PLoS medicine - Apr 16 2014]
BioAlliance and Topotarget merge to focus on ra... [Published PMLive - Apr 16 2014]
BioAlliance Pharma and Topotarget merge to crea... [Published Pharma Letter - Apr 16 2014]
BioAlliance Pharma and Topotarget Announce Merg... [Published PharmaceuticalProcessing - Apr 16 2014]
BioAlliance Pharma to merge with Topotarget [Published Manufacturing Chemist - Apr 16 2014]
Stress Makes the Clock Tick [Published PLoS Biology - Apr 16 2014]
Discovery of the First N-Hydroxycinnamamide-Bas... [Published Journal of Medicinal Chemistry - Apr 15 2014]
Inhibitors of histone deacetylase [Published Free Patents Online - Apr 15 2014]
The histone deacetylase inhibitor, LBH589, prom... [Published 7thSpace - Apr 15 2014]
Oncology: Researchers at Mackay Memorial Hospit... [Published NewsRX - Apr 15 2014]
Regenerating muscle in Duchenne muscular dystro... [Published Health Canal - Apr 14 2014]
Aiming to defeat HIV [Published Drug Discovery News - Apr 12 2014]
GSK-3β and Vitamin D Receptor are Involved in β... [Published Sexual Development - Apr 12 2014]
New Findings from Karolinska Institute Describe... [Published HispanicBusiness.com - Apr 10 2014]
Cdc4 turns over Hst3 [Genetics] [Published PNAS - Apr 08 2014]
MEI Pharma Adds Former VC David Urso as Senior ... [Published FinanzNachrichten.de - Apr 08 2014]
MEI Pharma Identifies Potential Biomarker For P... [Published FinanzNachrichten.de - Apr 07 2014]
Epigenetic inheritance [Published BioScreening - Apr 04 2014]
Epigenetic Mechanisms in the Pathogenesis of Di... [Published Sexual Development - Apr 03 2014]
Patent Issued for Host Cells Comprising Alpha 1... [Published 4 Traders - Apr 03 2014]
1 2 3
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Histone Deacetylase Inhibitors: Emerging Markets [Published PR Newswire: Health - Apr 21 2014]
WEST HARTFORD, Conn., April 21, 2014 /PRNewswire-iReach/ -- Global Information Inc. announces the addition of a new market research report "Histone Deacetylase Inhibitors: Emerging Markets" at GIIResearch.comThe global histone deacetylase inhibitor (HDI) ...
DOTW Keeps Tabs As Tax Trimming Fuels Deals [Published The IN VIVO Blog - Feb 28 2014]
As an industry, biopharma actually fares pretty well when it comes to taxes. Among profitable companies, biotech and pharma have some of the lowest effective U.S. tax rates compared to companies in other sectors. But that doesn’t mean they have stopped ...
1

Press Releases

sort by: Date | Relevance
Repligen Announces Asset Purchase Agreement Wit... [Published GlobeNewswire: Acquisitions News - Jan 21 2014]
BioMarin Announces Agreement With Repligen for ... [Published GlobeNewswire: Acquisitions News - Jan 21 2014]
Mirati Therapeutics to Present at the 25th Annu... [Published PR Newswire - Nov 22 2013]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.